Hexarelin: the strongest pulse in the family, and the fastest to stop working

The end of the potency scale that starts with ipamorelin. It produces the largest acute growth hormone pulse of the family and loses that ability faster than any of them, which makes it the one compound in this class where the schedule is the whole design.

Potency and tolerance are the same property

Established clinical use Hexarelin is a hexapeptide agonist at the ghrelin receptor, and across the growth hormone releasing peptides it produces the largest single GH pulse. It is also the least selective: cortisol and prolactin rise more than with GHRP-2 and considerably more than with ipamorelin.

Desensitisation is the defining practical limit. Strong, sustained agonism at a receptor reliably reduces its response, and hexarelin does this faster than any other compound in the family — measurably, within weeks of continuous use. That is why the app’s own dosing rows specify two to three times weekly rather than daily, with explicit breaks. Unlike most on-and-off schedules in this reference, this one has a pharmacological reason behind it rather than a convention.

The consequence for anyone comparing the class: hexarelin’s advantage is acute rather than sustained. If what you want is the biggest possible pulse from a single administration it wins; if what you want is a raised IGF-1 held over months, the more selective compounds get there and stay there.

The cardiac receptor is a genuinely separate story

Animal-only or theoretical Hexarelin binds CD36 in cardiac tissue, a receptor unrelated to the growth hormone axis, and the cardioprotective effects reported in animal work — improved left ventricular function, protection against ischaemia-reperfusion injury — appear to run through that binding rather than through growth hormone at all. GH receptor knockout models still show the cardiac effect, which is the evidence that separates the two.

That is one of the more interesting findings attached to any research peptide, and it has not been translated. There is no human trial of hexarelin for a cardiac indication, no approved use, and the app’s own cardiac dosing row is a research protocol rather than a therapy. Anyone with a cardiac condition reading that as a treatment option is reading it wrong, and it belongs with a cardiologist rather than as a self-directed decision.

What to measure

IGF-1 is the marker that tells you whether the axis moved, as across this whole class, and on this compound it doubles as the desensitisation check: a falling IGF-1 on an unchanged protocol is what tolerance looks like, and it does not announce itself as a symptom. The IGF-1 page covers the age-dependent reference interval.

Prolactin and cortisol are on this compound’s panel for a reason that does not apply to the selective ones — the prolactin page covers how easily that particular hormone is elevated by the draw itself, which matters when looking for a drug effect. Water retention is reported more here than elsewhere in the class, consistent with the size of the GH response.

Animal-only or theoretical There is no approved product and no controlled trial for the uses this is put to. Identity and purity rest with whoever made the vial, and this site names no vendor. Anything experienced while using it belongs with a clinician who has the full picture.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Hexarelin, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Prolactin
• IGF-1

Drawbacks and risks the app records

From the app’s own entry, and it reads as a coherent description of one property seen from six angles: this compound is the potent, unselective, fast-tolerating end of a family.

• Fastest desensitization of all GHRPs — limits chronic use
• Strongest cortisol and prolactin elevation of GHRPs
• Not suitable for daily long-term use
• Requires cycling to maintain effectiveness
• Water retention more pronounced
• Less selective than Ipamorelin

Interaction rules that name Hexarelin

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Why not use it daily?

Because it desensitises faster than anything else in the class — within weeks of continuous use. The intermittent schedule in the app’s rows exists for that pharmacological reason rather than as a general cycling convention.

Is the cardiac effect real?

In animal models, and it appears to run through CD36 rather than growth hormone — knockout models still show it. No human trial has tested it for a cardiac indication, and there is no approved use.

How does it compare to ipamorelin?

Larger acute pulse, much less selectivity — more cortisol and prolactin — and far faster tolerance. Ipamorelin was developed specifically to avoid the second and third of those.

How would I know it stopped working?

IGF-1 falling on an unchanged protocol. Tolerance does not produce a symptom, which is the argument for measuring rather than judging by feel.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.